Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934099 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
A Phase 2 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT03934099: Completed Phase 2 study, sponsored by LG Chem.
NCT03934099 is a Phase 2 study that has completed, run by LG Chem. The registered enrollment target is 156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03934099, a Phase 2 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Primary Outcome
sUA level was measured at Day 84
Interventions
- DRUG Placebo
- DRUG LC350189 formulated capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 2 |
What the finished NCT03934099 record still lists
NCT03934099 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03934099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03934099 about?
NCT03934099 is a clinical study titled "A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia". The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
What is the current status of trial NCT03934099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2019-12-02. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT03934099?
The interventions under investigation include: Placebo (DRUG), LC350189 formulated capsule (DRUG).
Who is sponsoring clinical trial NCT03934099?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03934099's enrollment target sits among peer trials
156 445th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI